GRAIL
reported full NHS-Galleri trial results at the 2026 ASCO Annual Meeting showing a substantial reduction in stage IV cancer diagnoses and a four-fold higher cancer detection rate, presented Pathfinder 2 results from more than 35,000 participants, and has submitted an FDA PMA application for Galleri.
- Country
- United States
- Ticker
- GRAL
Growth
Galleri MCED test
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Multi-cancer early detection (MCED) | diagnostics-medtech | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.